NL-OMON52565撤回4 期
P2y12-receptOr antagonist therapy in patients with coronary artery disease undergoing Percutaneous coronary intervention using an genotype-guided treatment STRATEGY - POPular Strategy
适应症
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 入组人数
- 3,526
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this study, a subject must meet all
- •of the following criteria:
- •Patients >= 18 years of age
- •Patients with CCS undergoing successful elective PCI
- •Patients with written informed consent as approved by the ethics committee
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •Contraindication to aspirin
- •Contraindication to prasugrel, ticagrelor or clopidogrel
- •Under the age of 18 years
- •Planned cardiac valve surgery
- •Need for chronic oral anticoagulation
- •PCI when admitted for ACS
- •Life expectancy < 1 year
- •Unable or unwilling to provide informed consent
- •Pregnancy
- •Suboptimal result of stenting as defined by the operator
- •Any other condition putting patient at excessive risk for bleeding with
- •Treatment with a strong CYP3A4 inhibitor or inducer
- •Treatment with a strong CYP2C19 inhibitor or inducer
- •History of definite stent thrombosis
研究者
相似试验
进行中（未招募）
1 期
Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who have undergone coronary blood flow restoration surgery with a stent (MATRIX-2)AF patients who have undergone successful PCIMedDRA version: 20.0Level: PTClassification code: 10051592Term: Acute coronary syndrome Class: 100000004849MedDRA version: 20.0Level: PTClassification code: 10003658Term: Atrial fibrillation Class: 100000004849MedDRA version: 24.0Level: PTClassification code: 10085242Term: Chronic coronary syndrome Class: 100000004849MedDRA version: 20.0Level: PTClassification code: 10003662Term: Atrial flutter Class: 100000004849CTIS2023-509717-36-00Insel Gruppe AG1,690
招募中
4 期
Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy - 2 Studycoronary artery diseasepercutaneous coronary intervention1001108210003216NL-OMON52027niversity of Florida College of Medicine50
进行中（未招募）
1 期
Tailoring blood thinners after percutaneous coronary interventioEfficacy of antiplatelet therapy after percutaneous coronary intervention in patients using oral anticoagulantsEUCTR2021-001418-12-NLniversity of Florida84
进行中（未招募）
1 期
REperfusion with P2Y12 inhibitors in addition to mEchanical thRombectomy for perFUsion imaging selected acute Stroke patiEnts : a multicentric randomized controlled trialpatients with a clinical diagnosis of AIS consecutive to LVO between 0 and 24 hours of symptom onset and selected by perfusion imagingEUCTR2020-005451-20-FRFondation A. de Rothschild Hospital368
进行中（未招募）
1 期
Reperfusion with P2Y12 inhibitors in addition to mechanical thrombectomy for perfusion imaging selected acute stroke patients : a multicentric randomized controlled trialCTIS2024-516163-88-00Fondation A De Rothschild368